Staidson BioPharm announced that on October 24, 2025, it received a notice from the Shenzhen Stock Exchange that its application documents for issuing shares to specific objects have been accepted. This issuance still needs to be approved by the Shenzhen Stock Exchange and obtain the registration decision from the China Securities Regulatory Commission before it can be implemented. There is uncertainty regarding whether it will pass the review and the timeline, and the company will disclose progress in a timely manner